Patient 1: Patient 2:

Similar documents
Cancer Cases Treated and Results


West of Scotland Cancer Network Guideline for Managing Chemotherapy Induced Nausea and Vomiting

MASCC Guidelines for Antiemetic control: An update

ASSESSMENT OF THE PAEDIATRIC NEEDS CHEMOTHERAPY PRODUCTS (PART I) DISCLAIMER

Emetogenicity level 1. Emetogenicity level 2

CANCER PREVENTION AND ACCESS TO MEDICINES. Gracemarie Bricalli ESMO Head of International Affairs

Appendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2

Surveillance after Treatment of Malignancies. John M. Burke, M.D. March 2013

Form 2023 R2.0: Ovarian Cancer Pre-HSCT Data

Lipoplatin monotherapy for oncologists

GUIDELINES FOR ANTIEMETIC USE IN ONCOLOGY SUMMARY CLASSIFICATION

COST CONSIDERATIONS Union for International Cancer Control 2014 Review of Cancer Medicines on the WHO List of Essential Medicines!!!!!!!!!

through the cell cycle. However, how we administer drugs also depends on the combinations that we give and the doses that we give.

It is a malignancy originating from breast tissue

Guidelines on Chemotherapy-induced Nausea and Vomiting in Pediatric Cancer Patients

Medical Therapies in Ovarian Cancer The Arabic Perspectives. Mezghani Bassem -Tunisia

Female Health Issues after Treatment for Childhood Cancer

VI.2 Elements for a Public Summary VI.2.1 Overview of Disease Epidemiology Acute Nausea and Vomiting (N&V) Etiologies:

Adult Intravenous Systemic Anticancer Therapy (SACT) Section A. SUMMARY of SCHEME QIPP Reference

Working Formulary January 2013 Oncology Chemotherapy Regimens

DRUG EXTRAVASATION. Vesicants. Irritants

Guidelines for the Use of Anti-Emetics with Chemotherapy

Rare ovarian tumours Page 1 of 6 Ovacome

Guideline Update on Antiemetics

Advances in Chemotherapy for Non-Small Cell Lung Cancer

IVC History, Cancer Research

Haematology, Oncology and Palliative Care Directorate.

FOR A HIGHER DEGREE OF CONFIDENCE

Adjuvant/Curative/Neo-adjuvant High Grade and Burkitt s Lymphoma Regimens. High Grade Lymphoma

Protocol Number Tumour Group Protocol Name on NCCP website 22/02/ Lung Afatinib Monotherapy 244 Gastrointestinal Regorafenib Monotherapy

SELECTING THE RIGHT HAND PROTECTION WHEN WORKING WITH CHEMOTHERAPY DRUGS

TRANSPARENCY COMMITTEE OPINION. 29 April 2009

National Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007

Hodgkin's Lymphoma. Symptoms. Types

Ovarian Cancer Survival. Ovarian Cancer Follow-up. Ovarian Cancer Treatment. Management of Recurrent Ovarian Carcinoma. 15,520 cancer deaths

CoQ10 and Cancer Treatment

Defining the Emetogenicity of Cancer Chemotherapy Regimens: Relevance to Clinical Practice

Medicinae Doctoris. One university. Many futures.

Vasco OP Underglove Sterile Surgical and Protective Gloves

1 The Cancer Programs Regulation (AR 242/98) is amended by this Regulation.

Vasco Nitril blue Non sterile Examination and Protective Gloves

Adverse effects of anticancer drugs (Antimetabolites agents, Alkylating agents, Antimicrotubule agents, Miscellaneous agents, Immune therapies and

MEDICAL NECESSITY GUIDELINE

Why do patients take herbs and nutritional supplements?

Index. Note: Page numbers of article titles are in boldface type.

StrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient

The problem. The treatment. Special situations. Brief background on HBV Definitions of HBV reactivation. The role and timing of antiviral therapy

Job title: Consultant Pharmacist/Advanced Practice Pharmacist

Medication Review. Cancer Chemotherapy Drugs. Pharmacy Technician Training Systems Passassured, LLC

Clinical Management Guideline for Breast Cancer

Foo Koon Mian Pharmacy Resident National University of Singapore Hematology / Oncology Pharmacy Residency Program. 4th APOPC November 2012

Breast Cancer Breast Managed Clinical Network

General Authorization Criteria for ALL Agents and Indications:

What is Cancer? Petra Ketterl, MD Medical Oncology and Functional Medicine

SCI. SickKids-Caribbean Initiative Enhancing Capacity for Care in Paediatric Cancer and Blood Disorders

Vasco OP Free Sterile Surgical and Protective Gloves

National Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy

Primary malignant neoplasms, not lymphatic or hematopoietic. Secondary malignant neoplasms (i.e.metastatic) Malignant neoplasm, unknown site

CCC Chemotherapy Protocols V9.0

Vasco OP Sensitive Sterile Surgical and Protective Gloves

Protocol Number Intrathecal Methotrexate for CNS 01/02/2018 Prophylaxis in GTN Gynaecology 249

APPHON/ROPPHA Guideline for the Prevention and Management of Chemotherapy Induced Nausea and Vomiting in Children with Cancer

COME HOME Innovative Oncology Business Solutions, Inc.

Female Health Issues after Treatment for Childhood Cancer

Regimens highlighted in red contain an expensive drug that is not currently publicly funded for the regimen and treatment intent.

1. Purpose Documentation Description.1 4. References 8 5. Cross-References.8 6. Development of the guideline.8

Oncology member story: Barbara

Objective: To provide a standard procedure for the recycling of unused medication and the disposal of medicines across all BCPFT Hospital sites.

Cancer Chemotherapy. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan December 2018

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

STEP 2: Identification of recurrence (local, regional or distant metastases) based on electronic health record algorithm using automated databases:

STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER

To help doctors give their patients the best possible care, the American

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Pazopanib (Votrient) Reference Number: ERX.SPA.139 Effective Date:

Lymphoma. What is cancer? What are signs that my cat has lymphoma. How is Lymphoma diagnosed?

Pharmacy Prior Authorization Colony Stimulating Factor (CSF)/Myeloid Growth Factor (MGF) Clinical Guideline

World Health Organization: Essential Medicines and Devices for Cancer:

ESCMID Online Lecture Library. by author

Use of Prophylactic Growth Factors and Antimicrobials in Elderly Patients with Cancer: A

THE ESMO INTERNATIONAL ANTINEOPLASTIC MEDICINES SURVEY: HOW AVAILABLE ARE THE WHO ESSENTIAL CANCER MEDICINES?

The Four-Dimensional Thought in Cancer Treatment

Elements for a Public Summary

Supplementary Appendix

See Important Reminder at the end of this policy for important regulatory and legal information.

OPCS Classification of Interventions and Procedures Version 4.6 (April 2011)

ICON Formulary - October 2018 Legend - ICON Protocols Essential (previously Standard), Core, Enhanced Core, Enhanced Enhanced

Chemotherapy induced emesis: Are we doing are best? David Warr University of Toronto

Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients

COME HOME Innovative Oncology Business Solutions, Inc.

Essentials. Oncology Practise Essentials. Oncology Basics. Tutorial 2. Cancer Chemotherapy

Principles of chemotherapy

Treatment of tumours Cancer therapy

The CTR-Test predicts the clinical failure of drug therapy with over 95% accuracy. 1. CTR-Test. Chemotherapy- Resistance-Test

SARASOTA MEMORIAL HOSPITAL

CENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 April May

Transcription:

Appendix A Compiled by Dr. Raymond Ngeh and Dr. Robert Luk Clinical notes and PET/CT scan images of eleven patients: 1. Middle age woman has cancer of the pancreas in the body of the gland. After just 2 treatments, the cancer has gone into remission, but we must continue treatment so that the cancer does not come back. 2. Middle age woman with massive primary cancer of the liver (hepatocellular carcinoma) and her condition is very bad: cannot walk, very weak. The cancer specialist said no need to do anything as she will die in a few weeks. After 4 treatments, the cancer is in remission, and the patient is up and about, very healthy. 3. Left breast cancer treated but came back and invaded the left anterior chest wall, and resisted all treatment. After about 8 treatments, almost all the cancer is in remission. 4. Middle age man treatment for cancer of the pancreas, but the cancer spread to the left abdomen and abdominal wall. Had tried all cancer treatment but failed. After 4 treatments, about half the cancer is in remission, and treatment will continue. 5. Middle age woman treated for cancer of the uterus. Cancer came back and spread, and failed all treatment. After 8 treatments, almost all the cancer is in remission. 6. Another cancer of the uterus spread to the abdomen and chest. After just 2 treatments, most of the cancer went into remission. 7. Cancer of the breast spreading to the bones. After 8 treatments, most of the cancer went into remission. 8. Young boy with brain glioma. Failed treatment, and the cancer went to the spinal cord and he was paralyzed. After 4 treatments, all the cancer went into remission. 9. Old man with cancer of the right lung. Refused all treatment, but we convinced him to try our treatment. After 3 treatments, the cancer size reduced to about half. 10. Young woman treatment for breast cancer about 10 years ago. Latest scan showed cancer has spread to the liver and to the bones. After 4 treatments, all the cancer is less active. 11. Prostate cancer, having survived about 10 years but became resistant to hormones and chemo drugs, and cancer has spread to most of the skeleton. His doctor gave up. After 2 treatments, bone metastases are less active. After another 4 treatments all the bone metastases became inactive. He is still in remission and now undergoing monthly follow-up.

Patient 1: A middle age woman has cancer of the pancreas in the body of the gland. If the cancer is in the head or in the tail, it can be operated, but in the body, cannot operate. Chemotherapy/radiotherapy for pancreatic cancer cannot cure but just prolong life. After just 2 treatments, the cancer has gone into remission, but we must continue treatment so that the cancer does not come back. Patient 2: Middle age woman with massive primary cancer of the liver (hepatocellular carcinoma) and her condition is very bad: cannot walk, very weak. There is no effective treatment today for this kind of cancer, so the cancer specialist said no need to do anything as she will die in a few weeks. After 4 treatment, the cancer is in remission, and the patient is up and about, very healthy.

Patient 3: Middle age women treated for left breast cancer. The cancer came back and invaded the left anterior chest wall, and resisted all treatment. After about 8 treatments, almost all the cancer is in remission. Patient 4: Middle age man treatment for cancer of the pancreas, but the cancer spread to the left abdomen and abdominal wall. Had tried all cancer treatment but failed. After 4 treatments, about half the cancer is in remission, and treatment will continue.

Patient 5: Middle age woman treated for cancer of the uterus. Cancer came back and spread, and failed all treatment. After 8 treatments, almost all the cancer is in remission. Patient 6: Another cancer of the uterus spread to the abdomen and chest. After just 2 treatments, most of the cancer went into remission.

Patient 7: Cancer of the breast spreading to the bones. After 8 treatments, most of the cancer went into remission. Patient 8: Young boy with brain glioma. Failed treatment, and the cancer went to the spinal cord and he was paralysed. After 4 treatments, all the cancer went into remission.

Patient 9: Old man with cancer of the right lung. Refused all treatment, but we convinced him to try our treatment. After 3 treatments, the cancer size reduced to about half. Patient 10: Young woman treatment for breast cancer about 10 years ago. Latest scan showed cancer has spread to the liver and to the bones. After 4 treatments, all the cancer is less active.

Patient 11: After 2 treatments Prostate cancer, having survived about 10 years but became resistant to hormones and chemo drugs, and cancer has spread to most of the skeleton. His doctor gave up. After 2 treatments, bone metastases are less active. Patient 11: Same Patient after 4 treatments After another 4 treatments all the bone metastases became inactive. He is still in remission and now undergoing monthly follow-up.

Appendix B HiCLoChemo Treatment formula and protocol by Dr. Raymond Ngeh and Dr. Robert Luk Disclaimer This is not an approved cancer treatment. It is intended to be used for clinical trials only under the supervision of oncologists, cancer research scientists or licensed medical staff only. Researchers or oncologists wishing to conduct clinical trials are welcome to get in touch with the corresponding author, c.p. Ong at cp11ong@gmail.com or at 1-240-888-2491. This new cancer HiCLoChemo treatment is developed by: Dr. Robert Luk Tel (6)07-2783333 and Dr. Raymond Ngeh Tel: (6)07-2228332 Introduction: HiCLoChemo is the abbreviation for HIGH DOSE VITAMIN C LOW DOSE CHEMOTHERAPY. This new cancer treatment involves the perfusion of high dose IV vitamin C followed immediately by the perfusion of a combination of 3 old cheap generic chemotherapy drugs at one third the usual dose. It can be used for all types and all stages of cancers. It can also be used for non-solid cancers like leukemia and myeloma. There are no severe side effects, so this is ideal for cancer patients who are put off by the severe side effects usually associated with conventional chemotherapy. Just like for conventional chemotherapy, cancer patients must have reasonably good liver and kidney functions, so before starting treatment, and from time to time, blood test for liver and kidney functions must be done. Before every treatment, full blood count is required. The reasons for this new cancer treatment working better than others are: 1. Chemotherapy immediately following perfusion of high dose IV vitamin C. 2. High dose IV vitamin c at 1.5 gram to 2.0 gram per kg of patient weight. 3. Combination of 3 chemotherapy drugs at low dose. Step 1: A PET/CT scan is done one or a few days before the start of treatment, in order to know the extent and activity of cancer lesions, for comparison with PET/CT after treatment. Step 2: On day 1, perfusion of 1.5g to 2.0g of vitamin C (PURE ascorbic acid) per kg of patient weight, in about 500ml of fluid, to be done in about 60 minutes. Step 3: Followed immediately with perfusion of a combination of 3 old, cheap, generic chemotherapy drugs, at about one third the usual dose, in about 500ml of fluid, to be done in about 30 minutes. Step 4: One week later, on day 8, repeat the same treatment. Step 5: About one week after the second treatment, on day 14, another PET/CT is done and compared with the first PET/CT, to see if there is any improvement. If there is significant improvement, go to Step 7. Step 6: If there is no improvement, a new treatment is started using another combination of 3 old, cheap, generic chemotherapy drugs. About one week after the second treatment, a PET/CT is done to see if there is improvement. If still no improvement, a third treatment is started using a new combination of 3 old, cheap, generic chemotherapy

drugs, and a PET/CT is done about one week after the second treatment, like before. If there is still no improvement after the third combination of chemotherapy drugs, then the case is considered a failure. Step 7: When there is significant improvement, then the same treatment is done once a week for 4 weeks. After 4 treatments, once a week, another PET/CT is done to see the progress. If the progress is good, the treatment can be spaced out to once every 2 weeks. If the progress is slow, treatment remains at once a week. After 4 treatments, another PET/CT is done to gauge the progress. If the progress is good, then the treatment can be done once every 3 weeks. This will continue until the cancer lesions have no more detectable activity in the PET/CT scan. Step 8: When no more activity is detected in the cancer lesions, the cancer is considered to be in remission, but cancer tends to reappear if left at this stage, so regular follow-up is done once a month with a PET/CT scan to confirm remission, and one treatment is given, as a precaution. Step 9: Monthly follow-up like this will continue for up to 6 months. If the remission is intact after 6 months of monthly follow-up, the interval of follow-up can be increased to 2 months, then 3 months, then 4 months, then 5 months, then 6 months. Follow-up at 6 months interval will be maintained until 5 to 10 years, when the cancer may be considered cured. A list of old generic chemo drugs used, but not intended to be exclusive: cisplatin, carboplatin, oxaliplatin methotrexate fluorouracil vincristine, vinblastine paclitaxel, docetaxel doxorubicin, epirubicin cyclophosphamide carmustine, lomustine procarbazine, dacarbazine gemcitabine irinotecan ifosfamide vinorelbine bleomycin etoposide